ArticleJournal of psychiatry & neuroscience : JPN2004
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response.
Article in Journal of psychiatry & neuroscience : JPN, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- The role of neuropeptides in suicidal behavior: a systematic review.BioMed research international · 2013Pooled it
- Tachykinin Receptors and their Antagonists: Unraveling Their Role in Metabolic Disorders and Therapeutic Innovations.Current drug targets · 2025Review
- Substance P's Impact on Chronic Pain and Psychiatric Conditions-A Narrative Review.International journal of molecular sciences · 2024Review
- Chronic-Exposure Low-Frequency Magnetic Fields (Magnetotherapy and Magnetic Stimulation) Influence Serum Serotonin Concentrations in Patients with Low Back Pain-Clinical Observation Study.International journal of environmental research and public health · 2022Observational
- The Hypothalamic-Pituitary-Adrenal Axis and Serotonin Metabolism in Individual Brain Nuclei of Mice with Genetic Disruption of the NK1 Receptor Exposed to Acute Stress.Cellular and molecular neurobiology · 2018Article
- Investigation of the effect of homocysteinylation of substance P on its binding to the NK1 receptor using molecular dynamics simulation.Journal of molecular modeling · 2018Article
- Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management.CNS drugs · 2016Review
- Pain and depression: a neurobiological perspective of their relationship.Psychiatry investigation · 2015Review
- Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain.Pain · 2013Article
- The drugs don't work? antidepressants and the current and future pharmacological management of depression.Therapeutic advances in psychopharmacology · 2012Article
- Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.British journal of pharmacology · 2011Article
- Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release.Naunyn-Schmiedeberg's archives of pharmacology · 2007Article
- Synthesis of two potential NK1-receptor ligands using [1-11C]ethyl iodide and [1-11C]propyl iodide and initial PET-imaging.BMC medical imaging · 2007Article
- Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.Psychopharmacology · 2005Article
- Neurobiology of severe mental disorders: from cell to bedside 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal.Journal of psychiatry & neuroscience : JPN · 2004Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substance P (neurokinin-1 [NK1]) receptor antagonists appear to be effective antidepressant and anxiolytic agents, as indicated in 3 double-blind clinical trials. In laboratory animals, they promptly attenuate the responsiveness of serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE) neurons to agonists of their cell-body autoreceptors, as is the case for some antidepressant drugs that are currently in clinical use. Long-term, but not subacute, antagonism of NK1 receptors in rats increases 5-HT transmission in the hippocampus, a property common to all antidepressant treatments tested thus far. This enhancement seems to be mediated by a time-dependent increase in the firing rate of 5-HT neurons. Mice with the NK1 receptor deleted from their genetic code also have an increased firing rate of 5-HT neurons. Taken together, these observations strongly suggest that NK1 antagonists could become a new class of antidepressant and anxiolytic agents.
Indexed as
Identifiers
15173897PMC400690W2162738633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.